IL88534A - Rotavirus reassortants and vaccines containing them - Google Patents
Rotavirus reassortants and vaccines containing themInfo
- Publication number
- IL88534A IL88534A IL8853488A IL8853488A IL88534A IL 88534 A IL88534 A IL 88534A IL 8853488 A IL8853488 A IL 8853488A IL 8853488 A IL8853488 A IL 8853488A IL 88534 A IL88534 A IL 88534A
- Authority
- IL
- Israel
- Prior art keywords
- rotavirus
- human
- reassortant
- serotype
- gene
- Prior art date
Links
- 241000702670 Rotavirus Species 0.000 title claims abstract description 142
- 229960005486 vaccine Drugs 0.000 title claims abstract description 81
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 102
- 241000617996 Human rotavirus Species 0.000 claims abstract description 50
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 25
- 241000282414 Homo sapiens Species 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 46
- 241000283690 Bos taurus Species 0.000 claims description 39
- 238000004113 cell culture Methods 0.000 claims description 35
- 208000003322 Coinfection Diseases 0.000 claims description 15
- 241001471959 Bovine rotavirus A unknown G-type Species 0.000 claims description 11
- 206010067470 Rotavirus infection Diseases 0.000 claims description 9
- 241000288906 Primates Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 210000003292 kidney cell Anatomy 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 4
- 201000009840 acute diarrhea Diseases 0.000 claims description 3
- 230000002411 adverse Effects 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 241000702673 Bovine rotavirus Species 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000002238 attenuated effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000000120 cytopathologic effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000000521 hyperimmunizing effect Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000010530 Virus Neutralization Effects 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000005577 Gastroenteritis Diseases 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000012809 post-inoculation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 208000032754 Infant Death Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 229940099076 maalox Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 101150072531 10 gene Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229940124859 Rotavirus vaccine Drugs 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000020426 cherry syrup Nutrition 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100328537 Bos taurus C3 gene Proteins 0.000 description 1
- 101000908384 Bos taurus Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000702647 Human rotavirus strain WA Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000702678 Simian rotavirus A/SA11 Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical group O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12647787A | 1987-11-30 | 1987-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL88534A0 IL88534A0 (en) | 1993-12-08 |
| IL88534A true IL88534A (en) | 1994-02-27 |
Family
ID=22425038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8853488A IL88534A (en) | 1987-11-30 | 1988-11-29 | Rotavirus reassortants and vaccines containing them |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0323708B1 (de) |
| JP (1) | JP2818760B2 (de) |
| AT (1) | ATE128873T1 (de) |
| AU (1) | AU618973B2 (de) |
| CA (1) | CA1303525C (de) |
| DE (2) | DE122006000071I1 (de) |
| ES (1) | ES2079358T3 (de) |
| GR (1) | GR3018262T3 (de) |
| IL (1) | IL88534A (de) |
| LU (1) | LU91297I2 (de) |
| NL (1) | NL300252I2 (de) |
| ZA (1) | ZA888931B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU618963B2 (en) * | 1987-08-07 | 1992-01-16 | Institut Pasteur | Vaccines whose characteristic epitope is incorporated into a protein of picornavirus, in particular, poliovirus |
| US5626851A (en) * | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| WO1992001784A1 (en) * | 1990-07-26 | 1992-02-06 | The Wistar Institute Of Anatomy & Biology | Rotavirus reassortant vaccine |
| US5610049A (en) * | 1991-05-01 | 1997-03-11 | The Wistar Institute Of Anatomy And Biology | Human rotavirus HCR3A and method of growing said rotavirus |
| US5900238A (en) * | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
| ID20581A (id) * | 1996-10-18 | 1999-01-21 | Res Fnd For Micbial Diseases O | Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen |
| CN110903403B (zh) * | 2019-12-16 | 2021-07-13 | 中国农业大学 | 一种牛轮状病毒嵌合抗原以及检测牛轮状病毒抗体的胶体金免疫层析试纸卡 |
| KR102374547B1 (ko) * | 2021-05-31 | 2022-03-14 | 에스케이바이오사이언스(주) | 재배열 로타바이러스의 제조 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4571385A (en) * | 1983-06-27 | 1986-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors |
| US4636385A (en) * | 1985-02-15 | 1987-01-13 | The Wistar Institute Of Anatomy & Biology | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection |
-
1988
- 1988-11-28 AU AU26306/88A patent/AU618973B2/en not_active Expired
- 1988-11-29 IL IL8853488A patent/IL88534A/en active Protection Beyond IP Right Term
- 1988-11-29 CA CA000584371A patent/CA1303525C/en not_active Expired - Lifetime
- 1988-11-29 ZA ZA888931A patent/ZA888931B/xx unknown
- 1988-11-30 JP JP63301117A patent/JP2818760B2/ja not_active Expired - Lifetime
- 1988-11-30 DE DE19883854575 patent/DE122006000071I1/de active Pending
- 1988-11-30 AT AT88311331T patent/ATE128873T1/de active
- 1988-11-30 ES ES88311331T patent/ES2079358T3/es not_active Expired - Lifetime
- 1988-11-30 DE DE3854575T patent/DE3854575T2/de not_active Expired - Lifetime
- 1988-11-30 EP EP88311331A patent/EP0323708B1/de not_active Expired - Lifetime
-
1995
- 1995-11-30 GR GR950403377T patent/GR3018262T3/el unknown
-
2006
- 2006-12-14 NL NL300252C patent/NL300252I2/nl unknown
- 2006-12-20 LU LU91297C patent/LU91297I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2079358T3 (es) | 1996-01-16 |
| EP0323708B1 (de) | 1995-10-11 |
| IL88534A0 (en) | 1993-12-08 |
| GR3018262T3 (en) | 1996-02-29 |
| DE3854575T2 (de) | 1996-05-15 |
| EP0323708A1 (de) | 1989-07-12 |
| AU2630688A (en) | 1989-06-01 |
| JP2818760B2 (ja) | 1998-10-30 |
| LU91297I2 (fr) | 2007-02-20 |
| JPH02138970A (ja) | 1990-05-28 |
| DE3854575D1 (de) | 1995-11-16 |
| AU618973B2 (en) | 1992-01-16 |
| CA1303525C (en) | 1992-06-16 |
| ATE128873T1 (de) | 1995-10-15 |
| ZA888931B (en) | 1989-07-26 |
| DE122006000071I1 (de) | 2007-04-05 |
| NL300252I1 (nl) | 2007-01-01 |
| NL300252I2 (nl) | 2007-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clark et al. | Rotavirus isolate WI61 representing a presumptive new human serotype | |
| Midthun et al. | Reassortant rotaviruses as potential live rotavirus vaccine candidates | |
| AU773825B2 (en) | Rotavirus subunit vaccine | |
| Offit et al. | Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection | |
| US4636385A (en) | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection | |
| US5474773A (en) | Human rotaviruses, vaccines and method | |
| Mackow et al. | Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge | |
| US5626851A (en) | Rotavirus reassortant vaccine | |
| AU618973B2 (en) | Novel rotavirus reassortant vaccine | |
| CA2065847C (en) | Rotavirus reassortant vaccine | |
| US20090136545A1 (en) | Porcine rotavirus reassortant compositions | |
| US5610049A (en) | Human rotavirus HCR3A and method of growing said rotavirus | |
| KR20010072096A (ko) | 다가의 인간-소의 로타바이러스 백신 | |
| Brüssow et al. | Neutralizing antibodies to heterologous animal rotavirus serotypes 5, 6, 7, and 10 in sera from Ecuadorian children | |
| Shigeo et al. | Cold-adaptation of human rotavirus | |
| Ward et al. | Adult mouse model for rotavirus | |
| JPS62192325A (ja) | ワクチン、その製造法及びヒトのロ−タウイルス感染症に対するワクチン接種における使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXTF | Application for patent extension filed |